cervical cancer, endometrial carcinoma, uterine sarcoma
Conditions
Interventions
Product Name: Pembrolizumab
Product Code: MK-3475
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: PEMBROLIZUMAB
CAS Number: 1374853-01-4
Current Sponsor code: MK-3475
Other descriptive
Sponsors
University Hospital Ghent
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed endometrial carcinoma, cervical carcinoma or uterine sarcoma, refractory or persistent to chemotherapy or recurrent disease after at least one line of chemotherapy. 2. Be willing and able to provide written informed consent/assent for the trial. 3. Be > 18 years of age on day of signing informed consent. 4. Presence of an index lesion amenable to hypofractionated stereotactic radiotherapy 5. At least one lesion outside the radiation field that can be followed by imaging for clinical response according to RECIST and irRC 6. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion before and after radiotherapy if technically feasible. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor. 7. Have a performance status of 0 or 1 on the ECOG Performance Scale. 8. Patients on treatment with a proton pump inhibitor or anti-coagulant therapy should switch to the study regimen during the trial 9. Demonstrate adequate organ function, all screening labs should be performed within 10 days of treatment initiation. 10. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 11. Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 – Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 45 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20
Exclusion criteria
Exclusion criteria: 1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. 2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to the first dose of trial treatment, with the exception of patients with a contrast allergy; those patients are allowed to take steroids on the days of tumor imaging 3. Has a known history of active TB (Bacillus Tuberculosis) 4. Hypersensitivity to pembrolizumab or any of its excipients. 5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 6. Has had prior chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. 7. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 2 weeks prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. 9. Has active autoimmune disease (eg. inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis) that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 10. Has known history of, or any evidence of active, non-infectious pneumonitis. 11. Has an active infection requiring systemic therapy. 12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 14. Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-scree
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Efficacy (objective response rate) at week 26 according irRC criteria ;Secondary Objective: Safety of the combination treatment Objective response rate at week 26 according to RECIST criteria Progression-free survival Best Overall Response Rate (BORR) Overall survival Quality of life assessment ;Primary end point(s): response rate at week 26 according to irRC ;Timepoint(s) of evaluation of this end point: week 26 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Safety according to CTCAE4.0 Response rate at week 26 according to RECIST Progression-free survival rate Best Overall Response Rate (BORR) Overall survival rate Quality of Life ;Timepoint(s) of evaluation of this end point: Safety: week 7 Response rate: week 26 Progression-free survival: time of disease progression Best Overall Response Rate (BORR): time of best response Overall survival: time of death Quality of Life: week 26 | — |
Countries
Belgium
Contacts
Public ContactJoke Tommelein
Bimetra Clinics
Outcome results
None listed